Tags

Type your tag names separated by a space and hit enter

New strategies in treating male lower urinary tract symptoms.
Curr Opin Urol. 2014 Jan; 24(1):29-35.CO

Abstract

PURPOSE OF REVIEW

Improved understanding of the pathogenesis of lower urinary tract symptoms (LUTS) has led to the development of new drugs to treat male LUTS. The review aims to give an overview to the new drugs and to compounds in the pipeline.

RECENT FINDINGS

Tadalafil, a phosphodiesterase type 5 inhibitor, is a drug newly approved for the treatment of male LUTS and a true new challenger for the current standard treatment with alpha1 blockers, particularly in men with concomitant erectile dysfunction. Botulinum toxin and mirabegron, a beta3 agonist, might be of value in treating persistent storage LUTS. Intraprostatic injections with botulinum toxin, NX-1207, and PRX302, need further evaluation but might be treatment alternatives in the future. Similarly, vitamin D3 receptor analogues (e.g., elocalcitol), gonadotropin-releasing hormone antagonists (e.g., cetorelix), and modulators of the cannabinoid system (e.g., fatty acid amide hydrolase inhibitors) need further evaluation in clinical studies. Other compounds, such as transient receptor potential vanilloid antagonists, Rho kinase inhibitors, purinergic receptor blockers, and endothelin targeting drugs, are still at experimental stages.

SUMMARY

Novel drugs for the treatment of male LUTS have been introduced recently. Clinical practice along with further trials will have to prove their value, along with other compounds that are still in their early phase of development.

Authors+Show Affiliations

aDepartment of Urology, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany bDivision of Urology, Federal University of São Paulo (RS), São Paulo, Brazil.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24285261

Citation

Füllhase, Claudius, et al. "New Strategies in Treating Male Lower Urinary Tract Symptoms." Current Opinion in Urology, vol. 24, no. 1, 2014, pp. 29-35.
Füllhase C, Soler R, Gratzke C. New strategies in treating male lower urinary tract symptoms. Curr Opin Urol. 2014;24(1):29-35.
Füllhase, C., Soler, R., & Gratzke, C. (2014). New strategies in treating male lower urinary tract symptoms. Current Opinion in Urology, 24(1), 29-35. https://doi.org/10.1097/MOU.0000000000000003
Füllhase C, Soler R, Gratzke C. New Strategies in Treating Male Lower Urinary Tract Symptoms. Curr Opin Urol. 2014;24(1):29-35. PubMed PMID: 24285261.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New strategies in treating male lower urinary tract symptoms. AU - Füllhase,Claudius, AU - Soler,Roberto, AU - Gratzke,Christian, PY - 2013/11/29/entrez PY - 2013/11/29/pubmed PY - 2014/7/22/medline SP - 29 EP - 35 JF - Current opinion in urology JO - Curr Opin Urol VL - 24 IS - 1 N2 - PURPOSE OF REVIEW: Improved understanding of the pathogenesis of lower urinary tract symptoms (LUTS) has led to the development of new drugs to treat male LUTS. The review aims to give an overview to the new drugs and to compounds in the pipeline. RECENT FINDINGS: Tadalafil, a phosphodiesterase type 5 inhibitor, is a drug newly approved for the treatment of male LUTS and a true new challenger for the current standard treatment with alpha1 blockers, particularly in men with concomitant erectile dysfunction. Botulinum toxin and mirabegron, a beta3 agonist, might be of value in treating persistent storage LUTS. Intraprostatic injections with botulinum toxin, NX-1207, and PRX302, need further evaluation but might be treatment alternatives in the future. Similarly, vitamin D3 receptor analogues (e.g., elocalcitol), gonadotropin-releasing hormone antagonists (e.g., cetorelix), and modulators of the cannabinoid system (e.g., fatty acid amide hydrolase inhibitors) need further evaluation in clinical studies. Other compounds, such as transient receptor potential vanilloid antagonists, Rho kinase inhibitors, purinergic receptor blockers, and endothelin targeting drugs, are still at experimental stages. SUMMARY: Novel drugs for the treatment of male LUTS have been introduced recently. Clinical practice along with further trials will have to prove their value, along with other compounds that are still in their early phase of development. SN - 1473-6586 UR - https://www.unboundmedicine.com/medline/citation/24285261/New_strategies_in_treating_male_lower_urinary_tract_symptoms_ L2 - https://doi.org/10.1097/MOU.0000000000000003 DB - PRIME DP - Unbound Medicine ER -